Children’s Medical Center has been granted a patent for a method involving the transplantation of hematopoietic cells to treat neurological diseases. The method includes administering CD34+ Hematopoietic Stem Progenitor Cells via Intra-cerebral Ventricular Injection to reconstitute microglia in patients at risk of lysosomal storage disorders or neurodegenerative diseases. GlobalData’s report on Children’s Medical Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Children's Medical Center, was a key innovation area identified from patents. Children's Medical Center's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of neurological diseases by reconstituting brain myeloid cells
A recently granted patent (Publication Number: US11957713B2) outlines a method for delivering Hematopoietic Stem Progenitor Cells (HSPC) to human subjects at risk of lysosomal storage disorders or neurodegenerative diseases. The method involves administering human CD34+ HSPC via Intra-cerebral Ventricular Injection (ICV) after prior treatment with a cytotoxic agent or radiation to ablate microglia and their progenitors. This administration aims to reconstitute microglia through HSPC engraftment in the subject, potentially offering a novel therapeutic approach for these conditions.
Furthermore, the patent details variations in the method, such as using CD38- CD34+ HSPC or CD150+ CD48- HSPC for ICV administration after cytotoxic treatment. The targeted lysosomal storage disorders include a range of conditions like Gaucher Disease and Niemann-Pick Disease, while neurodegenerative diseases like ALS and Alzheimer's Disease are also addressed. Additionally, the patent covers the use of Lin-Hematopoietic Stem Progenitor Cells, specifically c-kit- Sca-1+, for ICV delivery post-cytotoxic treatment to aid in microglia reconstitution. These methods offer potential advancements in the treatment of these debilitating diseases by leveraging the regenerative properties of HSPCs in the central nervous system.
To know more about GlobalData’s detailed insights on Children's Medical Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
